ACRV

Acrivon is a pre-revenue clinical-stage oncology company whose value rests entirely on its ACR-368 (prexasertib) and ACR-2316 candidates and the AP3/OncoSignature platform. The clinical signal is genuinely interesting: the 10-K reports a confirmed ORR of 39% in Arm 1 endometrial cancer, 44% in patients with two prior lines, and 52% in pooled serous EC — a high-unmet-need, aggressive tumor — which prompted the company to add Arms 3 and 4. That is the bull case, and it is real optionality. But optionality is not a balance sheet, and the numbers here describe a company that must raise money before that optionality can mature.

The financing math is the disqualifier. FY2025 operating cash flow was -$63.7M and net loss was -$77.9M, against just $41.5M of cash and equivalents. Total assets fell 34% and stockholders' equity fell 36% year over year, while shares outstanding already grew 23.6% — the dilution has started and, at a $1.78 stock, the next raise will be deeply dilutive to current holders. Management's own risk factors are explicit: 'We will need additional funding to meet our financial obligations... If we are unable to raise capital when needed, we could be forced to curtail our planned longer-term operations.' With under a year of runway at the current burn, a financing overhang dominates everything else.